Ipsen's MDM2 Bet: Novel Mechanism Meets an Unproven Combination Bar in Myelofibrosis

Ipsen Acquires Kartos Therapeutics, Bolstering Oncology Pipeline

Ipsen has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company, thereby adding the late-stage MDM2 inhibitor navtemadlin to its pipeline. Navtemadlin is in Phase III clinical development for myelofibrosis as an add-on therapy to ruxolitinib for patients with suboptimal response. The Phase III POIESIS study aims to evaluate if navtemadlin can improve clinical outcomes compared to ruxolitinib alone, with early data suggesting potential for clinically meaningful responses and disease-modifying benefits in intermediate and high-risk TP53wt myelofibrosis.

• Ipsen has successfully completed the acquisition of Kartos Therapeutics, a strategic move that significantly strengthens its late-stage oncology pipeline. This acquisition integrates navtemadlin, a promising MDM2 inhibitor, into Ipsen's portfolio, aligning with its focus on delivering transformative medicines in areas of high unmet need.
• Navtemadlin is an investigational oral MDM2 inhibitor undergoing Phase III clinical development. It is specifically being explored as an add-on therapy to ruxolitinib for myelofibrosis patients who exhibit a suboptimal response to the current standard of care, addressing a critical gap in treatment options for this challenging condition.
• The Phase III POIESIS study is designed to assess navtemadlin's ability to enhance clinical outcomes beyond ruxolitinib alone. Myelofibrosis is characterized by significant symptom burden and a high risk of progression, with a substantial proportion of patients discontinuing ruxolitinib due to inadequate response, underscoring the urgent need for novel, effective therapeutic strategies.

Addressing the Limitations in Current Myelofibrosis Treatment

Current myelofibrosis treatment is constrained by fundamental limitations across all available therapeutic modalities, leaving substantial unmet need — particularly for patients with advanced disease or those who have exhausted first-line options. While allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative intervention and JAK inhibitors represent the cornerstone of symptom management, neither approach adequately addresses the full disease burden.

• Allo-HSCT eligibility and toxicity: Transplantation is limited by significant treatment-related morbidity and mortality, including graft-versus-host disease, infectious complications, and a notably elevated risk of graft rejection specific to myelofibrosis. Non-relapse mortality and relapse rates further restrict the proportion of patients who are suitable candidates.

• Intrinsic limitations of JAK inhibitors: Agents such as ruxolitinib and fedratinib exert predominantly anti-inflammatory rather than truly disease-modifying effects. They demonstrate modest impact on bone marrow fibrosis and driver mutation allele burden, do not reduce the risk of blast phase transformation, and clinical resistance typically develops after 2–3 years of therapy.

• Cytopenia-driven treatment barriers: Dose-dependent myelotoxicity — particularly thrombocytopenia — significantly narrows the eligible patient population. Neither ruxolitinib nor fedratinib is recommended in patients with severe thrombocytopenia (platelets <50 × 10⁹/L), a subgroup that already carries a particularly poor prognosis.

• Poor outcomes following JAK inhibitor failure: No approved therapies exist beyond the JAK inhibitor class, and estimated median survival post-failure is approximately two years or less — with outcomes varying by failure pattern. This underscores the urgent need for agents with alternative mechanisms of action.

• Persistent anemia as an unmet need: Optimal anemia management in myelofibrosis remains an unresolved clinical challenge, and the search for combination partners capable of improving cytopenias, reducing bone marrow fibrosis, and inducing meaningful molecular responses is ongoing.

Beyond JAK: Navtemadlin's Place Among Emerging Myelofibrosis Targets

The therapeutic landscape for myelofibrosis is rapidly expanding beyond JAK inhibition, with investigational agents now targeting epigenetic regulation, apoptotic pathways, intracellular signaling, telomerase activity, and bone marrow fibrosis. Among epigenetic modifiers, BET (Bromodomain and Extraterminal Domain) inhibitors have emerged as particularly promising. Pelabresib (CPI-0610), which targets BET proteins to suppress expression of genes involved in critical oncogenic signaling, demonstrated compelling efficacy in the phase III MANIFEST-2 study — achieving spleen volume reduction ≥35% at week 24 in 65.9% of patients when combined with ruxolitinib, compared to 35.2% in the placebo plus ruxolitinib arm. LSD1 inhibition via bomedemstat represents another epigenetic avenue under active evaluation, alongside antifibrotic agents such as AVID200 and PRM-151, which directly target the mechanisms underlying bone marrow fibrosis.

Apoptotic pathway modulation is a second major area of focus. Navitoclax, a BCL-XL/BCL-2 inhibitor, targets anti-apoptotic BCL-2 family proteins that are overexpressed in myelofibrosis, with clinical data showing activity in combination with JAK inhibitors for relapsed or refractory disease and phase III trials currently ongoing. Within the same mechanistic space, navtemadlin — an MDM2 inhibitor — is being investigated as a non-JAK inhibitor monotherapy in the second-line setting, illustrating growing interest in p53 pathway reactivation as a therapeutic strategy. Telomerase inhibition via imetelstat has also shown meaningful clinical benefit in JAK inhibitor–relapsed/refractory patients, with the 9.4 mg/kg dose achieving a median overall survival of 29.9 months, bone marrow fibrosis improvement in 40.5% of patients, and variant allele frequency reduction of driver mutations in 42.1%.

Signaling pathway inhibition and innate immune targeting round out the emerging therapeutic portfolio. Parsaclisib, a PI3K inhibitor, is under evaluation in combination with ruxolitinib, while tasquinimod — which targets S100A8/S100A9 alarmins in the alarmin pathway — demonstrated synergistic lethality with ruxolitinib and BET inhibitors in preclinical models. Additional agents including selinexor, a selective inhibitor of nuclear export, and tagraxofusp, which targets CD123, are also in investigation, as is luspatercept, an erythroid maturation agent being explored for anemia management in this setting. Collectively, these programs span a broad mechanistic spectrum, with several candidates already in registrational-stage trials.

Navtemadlin: Ipsen's Strategic Play in Suboptimal Myelofibrosis

Ipsen's strategic acquisition of Kartos Therapeutics and its lead asset, navtemadlin, marks a significant move into the complex and evolving landscape of myelofibrosis (MF) treatment. This decision underscores the persistent challenges faced by patients with MF, particularly those who experience a suboptimal response to initial JAK inhibitor therapy like ruxolitinib. While JAK inhibitors have dramatically improved quality of life and symptom burden, they often fall short of providing deep, disease-modifying benefits, and outcomes after discontinuation remain poor.

Navtemadlin, an oral MDM2 inhibitor, offers a compelling mechanism by restoring p53 activity to induce apoptosis in malignant cells. This approach holds the promise of addressing the underlying pathophysiology of MF, rather than just managing symptoms. The ongoing Phase III POIESIS study is designed to evaluate navtemadlin as an add-on to ruxolitinib for patients with suboptimal response, aiming to improve key clinical endpoints such as spleen volume reduction and total symptom score. If successful, this could establish a new standard of care, offering a much-needed therapeutic option for a patient population with limited alternatives.

However, the path forward is not without its complexities. The clinical trial design, specifically isolating the incremental benefit of navtemadlin as an add-on, will require robust data to demonstrate a clinically meaningful improvement over ruxolitinib alone. Furthermore, the MF pipeline is experiencing an 'exponential expansion' of novel agents, including other combinations and monotherapies with diverse mechanisms of action. This intense competitive environment means navtemadlin will need to clearly differentiate itself. Finally, as an add-on therapy, its safety and tolerability profile in combination with ruxolitinib will be critical, given that adverse events are a common reason for JAK inhibitor discontinuation. Despite these considerations, Ipsen's investment reflects a strong belief in navtemadlin's potential to contribute to what many anticipate will be a 'golden era' in MF treatment, offering more personalized and effective strategies for patients.